Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis
Conditions
Interventions
BMS-986158
Ruxolitinib
+1 more
Locations
53
United States
Local Institution - 0069
Newport Beach, California, United States
Local Institution - 0090
Lake Mary, Florida, United States
Local Institution - 0043
New Orleans, Louisiana, United States
Local Institution - 0038
Worcester, Massachusetts, United States
Local Institution - 0033
Ann Arbor, Michigan, United States
Local Institution - 0045
Hackensack, New Jersey, United States
Start Date
March 22, 2021
Primary Completion Date
May 31, 2026
Completion Date
May 31, 2026
Last Updated
September 10, 2025
NCT06859424
NCT06343805
NCT05123365
NCT07104799
NCT05037760
NCT06164561
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions